BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20370365)

  • 1. Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient.
    Westbrook SD; Wiederhold NP; Vallor AC; Kotara S; Bernardo S; Lee SA; Kirkpatrick WR; Toro JJ; Freytes C; Patterson TF; Redding SW
    Med Mycol; 2010 May; 48(3):557-60. PubMed ID: 20370365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
    Al-Baqsami ZF; Ahmad S; Khan Z
    Sci Rep; 2020 Apr; 10(1):6238. PubMed ID: 32277126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite analysis and susceptibility to FCZ of Candida glabrata invasive isolates in Sfax Hospital, Tunisia.
    Abbes S; Sellami H; Sellami A; Makni F; Mahfoudh N; Makni H; Khaled S; Ayadi A
    Med Mycol; 2011 Jan; 49(1):10-5. PubMed ID: 20586679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates.
    Tsai HF; Sammons LR; Zhang X; Suffis SD; Su Q; Myers TG; Marr KA; Bennett JE
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3308-17. PubMed ID: 20547810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
    Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
    J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure.
    Arastehfar A; Daneshnia F; Salehi M; Yaşar M; Hoşbul T; Ilkit M; Pan W; Hagen F; Arslan N; Türk-Dağı H; Hilmioğlu-Polat S; Perlin DS; Lass-Flörl C
    Mycoses; 2020 Sep; 63(9):911-920. PubMed ID: 32413170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MALDI-TOF typing highlights geographical and fluconazole resistance clusters in Candida glabrata.
    Dhieb C; Normand AC; Al-Yasiri M; Chaker E; El Euch D; Vranckx K; Hendrickx M; Sadfi N; Piarroux R; Ranque S
    Med Mycol; 2015 Jun; 53(5):462-9. PubMed ID: 25841053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in genotype and fluconazole susceptibility of isolates from patients with Candida glabrata in Tunisia.
    Abbes S; Amouri I; Sellami H; Neji S; Trabelsi H; Cheikhrouhou F; Makni F; Ranque S; Ayadi A
    Therapie; 2014; 69(5):449-55. PubMed ID: 25285365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.
    Sanguinetti M; Posteraro B; Fiori B; Ranno S; Torelli R; Fadda G
    Antimicrob Agents Chemother; 2005 Feb; 49(2):668-79. PubMed ID: 15673750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic relationship of fluconazole non-susceptible Candida glabrata isolates from nine Korean hospitals.
    Kim SH; Shin JH; Joo MY; Lee MK; Lee HS; Kim MN; Shin MG; Suh SP; Ryang DW
    Mycoses; 2011 Sep; 54(5):e659-62. PubMed ID: 21605184
    [No Abstract]   [Full Text] [Related]  

  • 11. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping of clinical isolates of Candida glabrata from Iran by multilocus sequence typing and determination of population structure and drug resistance profile.
    Amanloo S; Shams-Ghahfarokhi M; Ghahri M; Razzaghi-Abyaneh M
    Med Mycol; 2018 Feb; 56(2):207-215. PubMed ID: 28482076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
    Bennett JE; Izumikawa K; Marr KA
    Antimicrob Agents Chemother; 2004 May; 48(5):1773-7. PubMed ID: 15105134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.
    Shin JH; Chae MJ; Song JW; Jung SI; Cho D; Kee SJ; Kim SH; Shin MG; Suh SP; Ryang DW
    J Clin Microbiol; 2007 Aug; 45(8):2385-91. PubMed ID: 17581937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species.
    Mann PA; McNicholas PM; Chau AS; Patel R; Mendrick C; Ullmann AJ; Cornely OA; Patino H; Black TA
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5026-34. PubMed ID: 19786600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance.
    Agnelli C; Guinea J; Valerio M; Escribano P; Bouza E; Muñoz P
    Rev Esp Quimioter; 2019 Aug; 32(4):395-397. PubMed ID: 31327188
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
    Borst A; Raimer MT; Warnock DW; Morrison CJ; Arthington-Skaggs BA
    Antimicrob Agents Chemother; 2005 Feb; 49(2):783-7. PubMed ID: 15673768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.
    Redding SW; Kirkpatrick WR; Saville S; Coco BJ; White W; Fothergill A; Rinaldi M; Eng T; Patterson TF; Lopez-Ribot J
    J Clin Microbiol; 2003 Feb; 41(2):619-22. PubMed ID: 12574256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata.
    Panackal AA; Gribskov JL; Staab JF; Kirby KA; Rinaldi M; Marr KA
    J Clin Microbiol; 2006 May; 44(5):1740-3. PubMed ID: 16672401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for isolation of fluconazole and echinocandin non-susceptible
    Papadimitriou-Olivgeris M; Spiliopoulou A; Fligou F; Tsiata E; Kolonitsiou F; Nikolopoulou A; Papamichail C; Spiliopoulou I; Marangos M; Christofidou M
    J Med Microbiol; 2021 Aug; 70(8):. PubMed ID: 34431765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.